XTLB
XTL Biopharmaceuticals
XTLB
XTLB
5 hedge funds and large institutions have $579K invested in XTL Biopharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 1 closing their positions.
Holders
5
Holders Change
–
Holders Change %
0%
% of All Funds
0.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
1
UBS Group
Zurich,
Switzerland
|
$11K |
| 2 |
2
Citadel Advisors
Miami,
Florida
|
$50K |
| 3 |
3
Morgan Stanley
New York
|
$2K |
Top Sellers
| 1 |
SM
1
Sabby Management
Miami Beach,
Florida
|
$434K |
| 2 |
TRCT
2
Tower Research Capital (TRC)
New York
|
$0 |
| Name | Market Value | Shares |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $434K | 724,134 | -27,155 | -4% |
|
2
Invesco
Atlanta,
Georgia
| $82K | 129,811 | – | – |
|
|
3
Citadel Advisors
Miami,
Florida
| $50K | 83,175 | +12,584 | +18% |
|
|
4
UBS Group
Zurich,
Switzerland
| $11K | 16,940 | +16,940 | New |
|
|
5
Morgan Stanley
New York
| $2K | 3,400 | +800 | +31% |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| – | – | -600 | Closed |
|